Biotechnology companies in Asia are in the rapid developing phase, and its potential for the regional and global influence for the next economic growth is promising. The factors contributing to the expectation are, highly educated human resource, rich funding and active government involvement to promote life science industry in the country.

  MediBIC has been anticipating the expansion of Asian market earlier, and carrying out R&D support based on the collaboration with experts in biotech industry and our global network.

  Our partnering strategy is to in-license the technologies from the U.S. and jointly develop the technology with companies in Asia. At the same time, we have been actively investing into business in Asia to build wide range of networks that would potentially lead to a rise of new technologies that support the R&D effort, and industry incubation. We are already seeing the good results from those investments.

  In recent years, it is not uncommon for companies [in the West] to expand into Asian market. However, there is no established model to enter into Asia, and the path to business expansion remains unclear to many companies. With our own global network and accumulated business experiences in Asia, we are able to offer a smoother entry into Asia for the companies that are anticipating to bring their business into this the key region for the future Life Science business.